Search

Search Constraints

You searched for: Author/Creator Herschorn, Sender

Search Results

1. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Issue 3 (June 2018)

2. Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis. Issue 1 (May 2017)

3. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder. (August 2014)

4. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE). Issue 5 (16th April 2017)

5. Cardiovascular Safety of the β3‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. (12th April 2018)

6. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. (3rd October 2017)

7. Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada. Issue 12 (30th December 2019)

9. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). (8th June 2017)

10. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. (June 2017)